Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Plus, alternatives for treatment if your protocol was impacted
CAS 68-19-9
The peptide effects depend on consistent use over time rather than any single dose
Additional risk factors include: Chronic kidney disease : Reduced renal clearance may impair B12 excretion Liver disease : Hepatic dysfunction can disrupt B12 metabolism and storage Myeloproliferative disorders : Certain blood cancers increase B12-binding proteins Concurrent medication use : Some drugs may interact with B12 metabolism, including metformin, proton pump inhibitors, and H2 antagonists Patients with these conditions should have B12 supplementation carefully monitored by their healthcare team
The FDA classifies BPC-157 as a Category 2 bulk drug substance meaning its not FDA-approved for human use and has been flagged as potentially presenting safety risks in unregulated compounding
Within the research-use-only designation that travels with each vial, sale to qualified Canadian research professionals for in vitro laboratory study is permitted
